Chester County News and Community Website
WILMINGTON, DE— Inhibikase Therapeutics, Inc. (Nasdaq: IKT) nearly doubled its second-quarter net loss as spending increased on its Phase 3 pulmonary arterial hypertension program, while a subsequent $50 million stock …
Inhibikase Loss Widens as Phase 3 PAH Trial Expands Read More
WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) has received U.S. Food and Drug Administration Orphan Drug Designation for its lead pulmonary arterial hypertension drug candidate, a regulatory milestone that …
Inhibikase Wins FDA Orphan Status for PAH Drug Candidate Read More
WILMINGTON, DE — Inhibikase Therapeutics (Nasdaq: IKT) granted stock options covering 981,243 shares of common stock to seven newly hired non-executive employees under its 2026 Inducement Equity Plan, the company …
Inhibikase Grants Equity Awards to New Employees Under Nasdaq Rule Read More WILMINGTON, DE — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) reported that it has secured regulatory clearance in 16 countries for its Phase 3 pulmonary arterial hypertension study, marking a key step …
Inhibikase Gains EU Clearance for Global PAH Trial Read More WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) has enrolled the first patient in its Phase 3 clinical trial evaluating IKT-001 for pulmonary arterial hypertension, advancing development of the drug …
Inhibikase Enrolls First Patient in Phase 3 PAH Trial Read More WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) granted stock options to five newly hired non-executive employees covering a total of 685,718 shares under its 2026 Inducement Equity Plan. The …
Inhibikase Grants Stock Options to Five New Employees Read More WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) recently granted stock options covering 685,718 shares to five newly hired non-executive employees under its 2026 Inducement Equity Plan, the company announced.
Inhibikase Grants Stock Options to New Employees Under Inducement Plan Read More